Palisade Bio (NASDAQ:PALI – Get Rating) and Brickell Biotech (NASDAQ:BBI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

7.9% of Palisade Bio shares are held by institutional investors. 11.4% of Palisade Bio shares are held by insiders. Comparatively, 4.5% of Brickell Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Palisade Bio and Brickell Biotech, as reported by MarketBeat.com.

Earnings and Valuation

This table compares Palisade Bio and Brickell Biotech's gross revenue, earnings per share and valuation.

Palisade Bio has higher earnings, but lower revenue than Brickell Biotech. Brickell Biotech is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Palisade Bio has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Brickell Biotech has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500.

Profitability

This table compares Palisade Bio and Brickell Biotech's net margins, return on equity and return on assets.

Summary

Palisade Bio beats Brickell Biotech on 10 of the 14 factors compared between the two stocks.

About Palisade Bio

(Get Rating)

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

About Brickell Biotech

(Get Rating)

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.